FIREFLY NEUROSCIENCE INC (AIFF)
US3179701012 - Common Stock
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients...
Firefly Neuroscience Closes on Financing of up to $12.4 Million
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman
TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds...
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)...
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly’s advanced AI...
Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder
Study to Leverage Firefly’s BNA™ Technology for Biomarker Identification, with Potential Applications for Broader Neurological Research...
Firefly Neuroscience to Participate in Upcoming October Investor Conferences
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
Partnership will expand Firefly’s FDA Cleared BNA™ technology to more hospitals and physician offices...
Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors
TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11
TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
NCD Will Integrate Firefly’s BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes...
UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq ...
Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq ...